NOTEWORTHY NEWS

 

15 Jun 2018

One-year results of ACCESS PTS study brings “hope” for post-thrombotic syndrome patients

The one-year results of the ACCESS PTS trial have shown that EKOS therapy (BTG) statistically improves post-thrombotic syndrome scores and sequelae as well as quality of life outcomes.

28 Apr 2018

OPTALYSE PE Results Presented at Society for Cardiovascular Angiography and Interventions

BTG plc (LSE: BTG), the global healthcare company, highlighted the presentation of OPTALYSE PE trial results at the Society for Cardiovascular Angiography and Interventions in San Diego, California. The findings further confirm that bilateral pulmonary embolism treated in as little as 2 hours with significantly less tissue plasminogen activator (tPA) than used in previous studies1- as low as 8mg total - show significant improvement in RV/LV ratio over both the short and long term and with a very low mortality rate of 2% and an equally low recurrent PE rate of 2%.

25 Aug 2016

Health Canada approves radiopaque bead for HCC, CRC liver metastases

BTG International Canada Inc. announced it received approval for its drug-eluding device, the DC Bead LUMI, from Health Canada. The bead is the first commercially available product for patients with hepatocellular carcinoma and colorectal cancer metastasized to the liver.

17 May 2016

Healthcare Player BTG on lookout for acquisitions a profits more than double

BTG, the technology healthcare company that develops products to shrink liver tumours and zap blood clots, has enjoyed a “coming of age”, its boss has said, after revealing that profits more than doubled last year.

6 May 2016

BTG snaps up cryogenic oncology specialist Galil for £58.3M

BTG Group is buying a US company that develops medical devices which kill tumours by freezing them, as it looks to further boost its presence in the world of interventional oncology.

12 Apr 2016

New procedure uses tiny beads to blast away liver cancer

Treating cancer that began in the liver or has spread to the liver can often involve months of chemotherapy and painful radiation treatments. But now there’s a new procedure that takes tiny beads that carry a high dose of radiation and sends them straight to the cancer.

5 Apr 2016

NICE highlights potential role of TheraSphere® for treatment of both operable and inoperable HCC

BTG plc (LSE: BTG), a global specialist healthcare company, has today announced the publication of a new medtech innovation briefing (MIB) by NICE (National Institute for Health and Care Excellence) for TheraSphere yttrium-90 glass microsphere therapy.1

30 Mar 2016

The ‘Pinhole’ Cancer Treatment You’ve Probably Never Heard of

Imagine an exquisitely precise cancer therapy procedure done through a small opening in the body

7 Jan 2016

Buyer Beware: Cultural Fit Can Make or Break a Deal

The announced $160 billion merger between Pfizer and Allergan in November was a fitting cap to a year of frenzied deal-making in pharmaceuticals and life sciences.

7 Jan 2016

An Army of Glass: The Remarkable Liver Cancer Treatment You Have Probably Never Heard Of

PATIENT PERSPECTIVE When Eleanor Cook’s cancer spread to her liver, it was a sign that something in her treatment regimen had to change.

7 Jan 2016

Cutting Edge Treatment Improves Prospects For Liver Cancer Patients

RESEARCH ADVANCES In October, iconic buildings throughout the United Kingdom were bathed in pink light. NFL players wore pink on their shoes during games across the U.S. and, in Canada, hundreds attended high-profile galas.

17 Dec 2015

BTG boss scans for next deals as lung device bet pays off 

After being vindicated in her 2014 purchase of a U.S. company with a device to prop open diseased lungs, the chief executive of British healthcare group BTG (BTG.L) is scouring the horizon for the next promising acquisition.

29 Sep 2015

Eisai Receives Additional Approval in Japan for Vascular Embolisation Device DC Bead® as Treatment of Hypervascular Tumors and Arteriovenous Malformations

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that it has received additional approval for the vascular embolization device DC Bead® (specially controlled medical device, “DC Bead”) to be used for the treatment of hypervascular tumors and arteriovenous malformations (AVM) in Japan.

29 Sep 2015

Creating a 'Contagious' Corporate Culture

The recent New York Times article on Amazon's "bruising workplace" sparked a firestorm of reaction.

5 Sep 2015

Millions of tiny beads help liver cancer patients

BILLINGS – Millions of tiny glass beads have given some liver cancer patients in Billings another option in their fight against the disease.

28 Apr 2015

UK Trial of radioactive glass particles to tackle cancer

Cancer treatment with radioactive glass microspheres is to be trialled for the first time in the UK at Oxford's Churchill Hospital.

22 Apr 2015

Banner - University Medical Center Phoenix named Center of Excellence radioembolization for liver cancer treatment

Banner - University Medical Center Phoenix has been named the West Coast Center of Excellence for TheraSphere®, a microsphere liver cancer treatment. The Phoenix hospital is one of only three locations in the United States to earn the prestigious recognition for radioembolization procedures and will be a training site for physicians throughout the country.

13 Feb 2015

DVT: Fixing Clots, Saving Lives

DVT: Fixing Clots, Saving Lives